This document summarizes a presentation on preventing diabetes and obesity in patients with mental health issues. It discusses how mental health disorders are associated with higher risks of diabetes and metabolic syndrome due to genetic and lifestyle factors as well as some medications used to treat mental health conditions. Treatment of diabetes and other vascular risk factors is essential for patients with mental health issues since premature death is often due to cardiovascular disease rather than suicide. The presentation emphasizes preventing and early identification of diabetes and metabolic syndrome through lifestyle counseling, monitoring weight and metabolic markers, and treating obesity and diabetes when present.
One of the best and latest presentations on obesity, sibutramine, orlistate, topimirate, phenteramine, xenical, serotonin reuptake inhibitor, lipase , pancreatic lipase inhibitor,
lipids, fats, major leg pullers/constraints in obesity management. Next Lipitor will also be from metabolic therapy.
One of the best and latest presentations on obesity, sibutramine, orlistate, topimirate, phenteramine, xenical, serotonin reuptake inhibitor, lipase , pancreatic lipase inhibitor,
lipids, fats, major leg pullers/constraints in obesity management. Next Lipitor will also be from metabolic therapy.
My seminar Obesity by Hani
Obesity is a public health and policy problem because of its increase prevalence, costs and health effect. (WHO, 2012, National heart lung and blood institute. 2012)
. The risk factor for chronic disease are highly prevalence (Zindah, Belbeisi, Walke & Makdad 2008)
The obesity and the overweight are risk for number of chronic disease include diabetes cardio vascular disease and cancer (WHO,2010)
This presentation was prepared for few of my colleagues at PSI working with me on a large scale diabetes and hypertension prevention program. The intent was to give them basic understanding of evidences around the impact of few lifestyle modification strategies particularly for caloric restriction and physical activity on health and lifespan.
Updates on obesity managment including basics and recent updates of 5 As of Canadian Obesity network
If any one needs this presentation you can email me Tarek1.mohamed@mu.edu.eg
INTRODUCTION, WHAT IS OBESITY, CLASSIFICATION OF OBESITY, MEASUREMENT OF OBESITY, BODY COMPOSITION AND FAT DISTRIBUTION, PREVALENCE OF OBESITY, HEALTH RISKS ASSOCIATED WITH OBESITY.
ETIOLOY OF OBESITY, PATHOGENESIS OF OBESITY,
INTERELATIONSHIP BETWEEN OBESITY AND PERIODONTITIS, OBESITY AND DENTAL PRACTICE
THERAPY FOR OBESITY
Tharwat's Family
Tharwat's Family
O B E S I T Y A N D T H E D I G E S T I V E S Y S T E M
Diet and exercise in management of obesity and overweight
Kwong Ming Fock* and Joan Khoo†
Departments of *Gastroenterology and †Endocrinology, Changi General Hospital, Singapore
Keywords
BMI, diet, exercise, NAFLD, obesity.
Accepted for publication 30 September 2013.
Correspondence
Professor Kwong Ming Fock, Division of
Gastroenterology, Department of Medicine,
Changi General Hospital, 2 Simei Street 3,
Singapore 529889. Email:
[email protected]
Abstract
According to World Health Organization, in 2010 there were over 1 billion overweight
adults worldwide with 400 million adults who were obese. Obesity is a major risk factor for
diabetes, cardiovascular disease, musculoskeletal disorders, obstructive sleep apnea, and
cancers (prostate, colorectal, endometrial, and breast). Obese people may present to the
gastroenterologists with gastroesophageal reflux, non-alcoholic fatty liver, and gallstones.
It is important, therefore, to recognize and treat obesity.
The main cause of obesity is an imbalance between calories consumed and calories
expended, although in a small number of cases, genetics and diseases such as hypothy-
roidism, Cushing’s disease, depression, and use of medications such as antidepressants and
anticonvulsants are responsible for fat accumulation in the body.
The main treatment for obesity is dieting, augmented by physical exercise and supported
by cognitive behavioral therapy. Calorie-restriction strategies are one of the most common
dietary plans. Low-calorie diet refers to a diet with a total dietary calorie intake of
800–1500, while very low-calorie diet has less than 800 calories daily. These dietary
regimes need to be balanced in macronutrients, vitamins, and minerals. Fifty-five percent
of the dietary calories should come from carbohydrates, 10% from proteins, and 30% from
fats, of which 10% of total fat consist of saturated fats. After reaching the desired body
weight, the amount of dietary calories consumed can be increased gradually to maintain a
balance between calories consumed and calories expended. Regular physical exercise
enhances the efficiency of diet through increase in the satiating efficiency of a fixed meal,
and is useful for maintaining diet-induced weight loss. A meta-analysis by Franz found that
by calorie restriction and exercise, weight loss of 5–8.5 kg was observed 6 months after
intervention. After 48 months, a mean of 3–6 kg was maintained.
In conclusion, there is evidence that obesity is preventable and treatable. Dieting and
physical exercise can produce weight loss that can be maintained.
Introduction
Since 1980, obesity has more than doubled globally and is now
considered as a major health hazard and a global epidemic. This
review aims to evaluate the current management of obesity and
overweight employing a combination of dietary interventions,
exercise, and behavioral modification. For ...
My seminar Obesity by Hani
Obesity is a public health and policy problem because of its increase prevalence, costs and health effect. (WHO, 2012, National heart lung and blood institute. 2012)
. The risk factor for chronic disease are highly prevalence (Zindah, Belbeisi, Walke & Makdad 2008)
The obesity and the overweight are risk for number of chronic disease include diabetes cardio vascular disease and cancer (WHO,2010)
This presentation was prepared for few of my colleagues at PSI working with me on a large scale diabetes and hypertension prevention program. The intent was to give them basic understanding of evidences around the impact of few lifestyle modification strategies particularly for caloric restriction and physical activity on health and lifespan.
Updates on obesity managment including basics and recent updates of 5 As of Canadian Obesity network
If any one needs this presentation you can email me Tarek1.mohamed@mu.edu.eg
INTRODUCTION, WHAT IS OBESITY, CLASSIFICATION OF OBESITY, MEASUREMENT OF OBESITY, BODY COMPOSITION AND FAT DISTRIBUTION, PREVALENCE OF OBESITY, HEALTH RISKS ASSOCIATED WITH OBESITY.
ETIOLOY OF OBESITY, PATHOGENESIS OF OBESITY,
INTERELATIONSHIP BETWEEN OBESITY AND PERIODONTITIS, OBESITY AND DENTAL PRACTICE
THERAPY FOR OBESITY
Tharwat's Family
Tharwat's Family
O B E S I T Y A N D T H E D I G E S T I V E S Y S T E M
Diet and exercise in management of obesity and overweight
Kwong Ming Fock* and Joan Khoo†
Departments of *Gastroenterology and †Endocrinology, Changi General Hospital, Singapore
Keywords
BMI, diet, exercise, NAFLD, obesity.
Accepted for publication 30 September 2013.
Correspondence
Professor Kwong Ming Fock, Division of
Gastroenterology, Department of Medicine,
Changi General Hospital, 2 Simei Street 3,
Singapore 529889. Email:
[email protected]
Abstract
According to World Health Organization, in 2010 there were over 1 billion overweight
adults worldwide with 400 million adults who were obese. Obesity is a major risk factor for
diabetes, cardiovascular disease, musculoskeletal disorders, obstructive sleep apnea, and
cancers (prostate, colorectal, endometrial, and breast). Obese people may present to the
gastroenterologists with gastroesophageal reflux, non-alcoholic fatty liver, and gallstones.
It is important, therefore, to recognize and treat obesity.
The main cause of obesity is an imbalance between calories consumed and calories
expended, although in a small number of cases, genetics and diseases such as hypothy-
roidism, Cushing’s disease, depression, and use of medications such as antidepressants and
anticonvulsants are responsible for fat accumulation in the body.
The main treatment for obesity is dieting, augmented by physical exercise and supported
by cognitive behavioral therapy. Calorie-restriction strategies are one of the most common
dietary plans. Low-calorie diet refers to a diet with a total dietary calorie intake of
800–1500, while very low-calorie diet has less than 800 calories daily. These dietary
regimes need to be balanced in macronutrients, vitamins, and minerals. Fifty-five percent
of the dietary calories should come from carbohydrates, 10% from proteins, and 30% from
fats, of which 10% of total fat consist of saturated fats. After reaching the desired body
weight, the amount of dietary calories consumed can be increased gradually to maintain a
balance between calories consumed and calories expended. Regular physical exercise
enhances the efficiency of diet through increase in the satiating efficiency of a fixed meal,
and is useful for maintaining diet-induced weight loss. A meta-analysis by Franz found that
by calorie restriction and exercise, weight loss of 5–8.5 kg was observed 6 months after
intervention. After 48 months, a mean of 3–6 kg was maintained.
In conclusion, there is evidence that obesity is preventable and treatable. Dieting and
physical exercise can produce weight loss that can be maintained.
Introduction
Since 1980, obesity has more than doubled globally and is now
considered as a major health hazard and a global epidemic. This
review aims to evaluate the current management of obesity and
overweight employing a combination of dietary interventions,
exercise, and behavioral modification. For ...
DEFINITION AND MEASUREMENT Obesity is a state of excess adipose tissue mass. Although often viewed as equivalent to increased body weight, this need not be the case—lean but very muscular individuals may be overweight by numerical standards without having increased adiposity.
Body mass index (BMI), which is equal to weight/height2 (in kg/m2 )
Body weights are distributed continuously in populations, so that choice of a medically meaningful distinction between lean and obese is somewhat arbitrary. Obesity is therefore defined by assessing its linkage to morbidity or mortality
Overweight And Obesity : Proven Health Risks, We All Should KnowSanjiv Haribhakti
Overweight and obesity are defined as abnormal or excessive fat accumulation in the body that presents a risk to health. Obesity will have a negative effect on health, leading to reduced life expectancy and/or increased health problems. According to WHO, Obesity is one of the most serious public health problems of the 21st century. For more info visit :- http://gisurgery.info/player_presentation.php?id=133
Iodine and the Thyroid: How the thyroid uniquely adapts to its environment to...HealthXn
This presentation describes how the thyroid actively traps iodine, a rare micronutrient, to produce thyroid hormones. Iodine is important for normal fetal and adult development.
This presentation given to the International Society for Enzymology in Corfu details the extent of vitamin D deficiency in the largest state of Australia, NSW. It highlights the over=testing phenomenon that has occurred and how to correct the problem.
The value of health information systems and EMR to patient careHealthXn
This presentation given to the Athena Society in Crete documents the challenges and benefits of health information systems and the difficulties encountered in implementing EMR.
Advances in the diagnosis and treatment for benign and malignant thyroid diseaseHealthXn
Thyroid disorders are common. This presentation reviews the causes of benign thyroid disease as well as therapy, including new therapies for advanced thyroid cancer.
Bridging health care’s innovation education gapHealthXn
Recently I was privileged to be part of a consultation bringing together CEOS in health, academia and business to examine health care's innovation education. Regina Herzlinger and co authors have distilled these consultations into this thought provoking article.
https://hbr.org/2014/11/bridging-health-cares-innovation-education-gap
Prevention against micronutrient malnutritionHealthXn
Micronutrident disorders are common and a major cause of morbidity in all populations. In this presentation we discuss the importance of iodine, folic acid and vitamin D deficiency. Prevention is the solution
The impact of maternal and fetal thyroid hormone deficiency: iodine deficienc...HealthXn
Thyroid hormone deficiency at critical periods of brain development may cause permanent mental and neurological disability and impairment. Iodine deficiency is the commonest preventable cause of mental disability
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Preventing diabetes and obesity in mental health disorders
1. Preventing Diabetes and
Obesity in Patients with
Mental Health
PROFESSOR STEVEN C. BOYAGES
THE UNIVERSITY OF SYDNEY, TUESDAY 18 TH OCTOBER 2016
WORLD FEDERATION FOR MENTAL HEALTH INTERNATIONAL CONFERENCE, CAI RNS AUSTRALIA
2. Outline
1. What is diabetes and its relation to obesity (prediabetes and metabolic syndrome)
2. Diabetes and Mental Health Co-Morbidity
3. Treatment of MH disorders may increase the incidence of diabetes and metabolic disorders
4. Premature vascular disease is the biggest killer of patients with MH
5. Treatment of other vascular risk factors is essential
6. Prevention and early identification of diabetes and metabolic syndrome is the key
3.
4. Diabetes and Mental Health Co-
Morbidity
1. Depression, anxiety disorders, dementia, schizophrenia, and bipolar disorder
(BD) occur more commonly in DM patients.
2. DM may be involved in the development of the first three conditions. The
exact mechanism by which DM may be linked to these conditions is not fully
understood.
3. There appears to be a bidirectional relationship between DM and
depression.
4. About 7% of DM cases are thought to be attributed to depression.
5. Depression is associated with a 60% to 65% increased risk of DM
6. DM appears to double the risk of dementia
6. Leading cause of death is vascular
disease
1. Despite the increased risk of suicide in psychiatric patients, the leading cause
of death in patients with schizophrenia or BD is cardiovascular disease (CVD).
2. This is especially true in younger patients, with the risk of CVD and stroke
more than two to three times greater than in a nonpsychiatric population.
3. MetS occurs in 37% to 63% of schizophrenia patients and in 30% to 49% of BD
patients.
4. Psychotropic medications used for managing mental illness can contribute to
the development of MetS.
7. Drug induced obesity and diabetes
Atypical antipyschotics (AA)
Among AAs, clozapine and olanzapine are associated with the
greatest weight gain
Quetiapine and risperidone with intermediate weight gain
Aripiprazole, paliperidone, and ziprasidone with the least
weight gain
Possible mechanisms for psychotropic-related WG include WG secondary to improved mood/affect;
increased food cravings; alterations in resting metabolic state; sedation; increased cellular
lipogenesis; and changes in neurotransmitters (e.g., 5-HT [serotonin] 1 and 2A/C receptor
antagonism) and neuropeptides (e.g., leptin, ghrelin, cytokines such as TNF)
9. Mechanism:
Obesity is the result of long-term energy imbalance whereby
energy intake surpasses expenditure
9
This imbalance may be caused
by a variety of intrinsic and
extrinsic factors
Hill JO et al. Circulation. 2012;126(1):126–32
10. Cause:
Factors contributing to energy imbalance
10
Energy
imbalance
Genetics
Inheritability
Epigenetic changes
Early life experience
Behaviour
Poor dietary habits
and physical inactivity
Medications
Social, political and
economic environment
Common medical
conditions
Leptin resistance
Hypothyroidism
Cushing’s syndrome
Depression
Sleep disturbances
Hormones
Hill JO et al. Circulation. 2012;126(1):126–32; Baqai N and Wilding JPH Obesity and metabolic complications
2015;43(2):73–76; National Health and Medical Research Council (2013) Clinical practice guidelines for the management
of overweight and obesity in adults, adolescents and children in Australia. Melbourne: National Health and Medical
Research Council.
Psychological
factors
Stress
Personal issues
Mood disorders
Depression
Disturbed eating
patterns
Eating disorders
Sociodemographic
factors
12. Who are the overweight or obese??
1.88 m
113 kg
BMI = 32
Obese, class I
1.57 m
130 kg 90 kg
1.75 m
BMI = 29.4
Overweight
BMI = 52.7
Obese, Class III
Based on weight and
height alone
Healthy weight
Taking into
consideration the
individual patient type
1.94 m
104 kg
BMI = 27.6
Overweight
12
13. Obesity is defined by the
World Health Organisation
as abnormal or excessive fat
accumulation that may impair
health1
Definition and measure of obesity
13
1. WHO. Fact sheet 311. Updates January 2015. Available at www.who.int/. 2. National Health and Medical Research Council (2013) Clinical practice
guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. Melbourne: National Health and Medical
Research Council.
Body Mass Index (BMI)
provides the most convenient
population-level measure of
overweight and obesity1
Waist circumference is a
good indicator
of total body fat and
a useful predictor of visceral
fat2
Compared with BMI, waist
circumference is a better predictor of
cardiovascular risk, type 2 diabetes in
women and metabolic syndrome2
14. Measures of obesity
14
Thresholds based on Caucasian population
Classification BMI (kg/m2)
Underweight <18.5
Normal range ≥18.5 and <24.9
Overweight ≥25 and <29.9
Obese ≥30
- Obese class I ≥30 and <34.9
- Obese class II ≥35 and <39.9
- Obese class III ≥40
Gender
Increased disease
risk
High
disease risk
Males ≥ 94 cm ≥ 102 cm
Females ≥ 80 cm ≥ 88 cm
BMI
Classification
Waist
Circumference
Measured midway
between the lower rib
margin and iliac crest
BMI = weight (kg)
height (m)2
National Health and Medical Research Council (2013) Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and
children in Australia. Melbourne: National Health and medical Research Council.
15. BMI and waist circumference thresholds
15
Patient groups
Waist circumference threshold
Women Men
South Asian, Chinese,
Japanese adults
≥ 80 cm ≥ 90 cm
Other ethnic groups,
e.g. Pacific Islanders
Higher than those of European
descent, not yet determined
Patient groups Distribution of fat
BMI (kg/m2)
thresholds
Aboriginal people High limb to trunk ratio Lower
Pacific Islander populations
(including Torres Strait Islander
peoples and Maori)
Higher proportion of lean body
mass
Higher
South Asian, Chinese and
Japanese population groups
More body fat at lower weights
Lower,
e.g. >23
People with high muscle mass
(e.g. athletes)
Lower proportion of body fat Higher
Older individuals
More body fat than a younger
individual at the same BMI
Lower
Adjustments are needed for different patient groups
National Health and Medical Research Council (2013) Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and
children in Australia. Melbourne: National Health and Medical Research Council.
17. Badman MK and Flier JS Science 2005;307:1909–14
Cause:
Hormonal regulation of energy balance
17
GLP-1, CCK, PYY, OXM Leptin Insulin, Amylin, PP
Gut Adipose tissue Pancreas
Satiety signals
Hypothalamus
Ghrelin
Gut
Hunger signal
Anorexigenic
neurons
Orexigenic
neurons
GLP-1, glucagon-like peptide-1; CCK, cholecystokinin; OXM, oxyntomodulin; PP, pancreatic polypeptide; PYY, peptide YY
Appetite
Hunger
Appetite
Satiety
Arcuate nucleus
18. Treatment options for weight
management and recommendations
18
Treatment intensification
Low
Meanweightloss
HighMedium
BMI 25-26.9
BMI 27-29.9
with risk factors and/or
comorbidities or
BMI > 30
Grima M and Dixon JB AFP 2013;42(8):532-41; National Health and Medical Research Council (2013) Clinical practice
guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. Melbourne:
National Health and Medical Research Council.
Lifestyle & Behavioural changes: Healthy eating, physical activity and psychological intervention
Reduced calorie diet/Very Low Energy diet
Anti-obesity medications
with weight loss of 5–10%
Bariatric surgery
BMI 35-39.9
with risk factors and/or
comorbidities or
BMI ≥40
19. Prevention of Obesity and Diabetes:
Principles
1. Record weight and other measures
2. Record degree of obesity
3. Check for diabetes and prediabetes and metabolic syndrome
4. Lifestyle advice, smartphone apps
5. Physical activity
6. Smoking cessation
7. Treat hypertension and lipids
8. Medication for obesity and diabetes
20. 5–10% weight loss is clinically meaningful
20
-20-15-10-50
Diabetes (Prevention)
Hypertension
Dyslipidaemia
Hyperglycaemia (elevated HbA1c)
Non-alcoholic fatty liver disease
Sleep apnoea
Osteoarthritis
Stress incontinence
Gastroesophageal reflux disease
Polycystic ovary syndrome
Health-related quality of life
Weight loss required for therapeutic benefit (%)
Obesitycomplication
Maximum benefit at 10%
Triglycerides still decreasing at >15%
HbA1C still decreasing at >15%
Improves steatosis, inflammation, and mild fibrosis
Improves symptoms and joint stress mechanics
5–10% in women; 10% in men
>10% optimal; lowers androgens, improves
ovulation, and increases insulin sensitivity
Continues to improve with weight-loss
Blood pressure still decreasing at >15%
Cefalu WT et al. Diabetes care 2015;38(8):1567-82. Wright F et al. J Health Psychol. 2013;18:574-86.
21. Approved anti-obesity medications
in Australia
211. Duromine™ Approved Product Information, July 1991. 2. Metermine Approved Product Information, July 2004.
3. Xenical® Approved Product Information, April 2000
• Approved in 1991/ 2004
• S4
• Private script
• Sympathomimetic amine
Duromine™ / Metermine
(Phentermine)1,2
• Approved in 2000
• S3
• Private script; available on the PBS under the Repatriation
Pharmaceutical Benefits Scheme
• Potent, specific and reversible long acting inhibitor of
gastrointestinal lipases required for the systemic absorption of
dietary triglycerides
Xenical® (Orlistat)3
22. New anti-obesity medication approved
for weight management in Australia
22Saxenda® Approved Product Information, December 2015
• Approved December 2015
• S4
• Liraglutide is a human glucagon-like peptide (GLP-1)
analogue, with 97% amino acid sequence homology to
endogenous human GLP-1
• Like endogenous GLP-1, liraglutide binds to and activates
the GLP-1 receptor (GLP-1R)
• GLP-1 is a physiological regulator of appetite and calorie
intake
Saxenda® (Liraglutide 3.0 mg)
23. Patients maintained a clinically meaningful
weight loss with liraglutide 3.0 mg
23
Week
Changeinweightfrom
baseline(%)
p<0.0001
-8.0%
-2.6%
-9.2%
-12
-10
-8
-6
-4
-2
0
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56
-3.5%
Liraglutide 3.0 mg + diet and exercise
72% completed 56 weeks of treatment
Diet and exercise alone
64% completed 56 weeks of treatment
p<0.001
Adapted from Pi-Sunyer 2015. Circle represents weight-loss at week 56 using Last Observation Carried Forward
(LOCF) imputation. Square represents weight-loss at week 56 using completer data set
Patients maintained a clinically meaningful weight
loss over 56 weeks with liraglutide 3.0 mg
Pi-Sunyer X et al. N Engl J Med 2015;373:11–22. Saxenda® Approved Product Information, December 2015
Mean baseline weight: 106 kg
Mean baseline BMI: 38.3
25. Inactivated
by DPP-4
DPP-4: dipeptidyl peptidase 4 enzyme;
GLP-1: glucagon-like peptide-1;
GIP: glucose-dependent insulinotropic polypeptide
Glucagon
(GLP-1)
Insulin
(GLP-1 and GIP)
Glucose
dependent
Pancreas
α
β
Ingestion of
food
GI tract Hepatic glucose
production
Glucose uptake
by peripheral
tissue
Liver
Glycogenesis
Gluconeogenesis
Incretins
GLP-1 and GIP
Blood glucose in
fasting and
postprandial states
Skeletal muscle
INCRETIN ACTIVITY CAN BE ENHANCED1-3
Adapted from:
1. Drucker DJ. Cell Metab 2006; 3: 153–65. 2. Ludwig DS. J Am Med Ass 2002; 287: 2414–23.
3. Dunning BE and Gerich JE. Endo Rev 2007; 28: 253–83.
26. 1. Diabetes in control.com Available from www.diabetesincontrol.com/contact-us/5139 [Accessed 2/2/13]
+ Dr John Eng
in 1992
Exendin-4
Exenatide
H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-
Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-
Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-
Pro-Pro-Pro-Ser-NH2
Gila lizard saliva
His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-
Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-
Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
+ Amylin
Pharmaceuticals
in 1996
DEVELOPMENT OF BYETTA (EXENATIDE)
27. 1. Klonoff DC et al. Curr Med Res Opin 2008; 24: 275–86. 2. Byetta Approved Product Information.
• Weight loss >1.5 kg per
week has been observed
in patients treated with
exenatide2
• Weight loss of this rate
may have harmful
consequences2
†Secondary endpoint.1 *Byetta is not indicated as a weight reduction agent.2
BYETTA 10 μg BID PROVIDED LONG-TERM
GLYCAEMIC CONTROL WITHOUT WEIGHT GAIN
AND WITH WEIGHT LOSS OVER 156 WEEKS1*†
28. Glucose input >250 g/day: Glucose uptake >250 g/day:4
Dietary intake >180 g/day
Increased glucose production3
– Gluconeogenesis*
– Glycogenolysis
Brain ~125 g/day
Rest of the body >125 g/day
Increased reabsorption and
recirculation of glucose
Glucose filtered
~360 g/day†
Glucose levels exceed the
glucose reabsorption
threshold, resulting in
glucosuria1
*Elevated glucose production in patients with Type 2 diabetes attributed to hepatic and renal gluconeogenesis.3
†Assumes a maximum renal absorption of 200 mg/dL2 and a daily filtration rate of 180 L/day3
1. Chao EC, et al. Nat Rev Drug Discov 2010;9:551–9; 2. Marsenic O. Am J Kidney Dis 2009;53:875–83. 3. Gerich JE. Diabet
Med 2010;27:136–42. 4. Wright EM, et al. J Int Med 2007;261:32–43.
Type 2 diabetes glucose input and uptake1-4
29. Dapagliflozin:
Removes excess glucose via the kidneys1,2 and
acts independently of insulin mechanisms
1. Gerich JE, Bastien A. Expert Rev Clin Pharmacol 2011;4:669−683.
2. FORXIGA (dapagliflozin) Product Information.
Increased urinary excretion
of excess glucose (~70 g/day)
Glucose
filtration
SGLT2
SGLT2
Dapagliflozin
Glucose
Dapagliflozin
Reduced glucose
reabsorption
Distal
tubule
Loop of
Henle
Glomerulus
Proximal
tubule
30. Dapagliflozin plus metformin IR:
Change in Weight† Over 208 Weeks1-4
(compared to SU plus metformin IR)
1. FORXIGA Product Information. 2. Del Prato S et al. Diabetes Obes Metab 2015; 17:581-590. 3. Nauck MA, et al.
Diabetes Care 2011;34:2015–2022. 3. Nauck MA, et al. Diabetes Care 2011;34:2015–2022. 4. Nauck MA et al.
Diabetes Obes Metab 2014; 16:1111-1120
*Data are adjusted mean change from baseline ±95% CI
derived from a longitudinal repeated-measures mixed model.
Weight reduction with dapagliflozin at 52 weeks was maintained up to 208 weeks,
whereas weight gain with glipizide at 52 weeks remained stable 1,2
Adapted from Del Prato S, et al.1,2
†Dapagliflozin is not indicated as a weight loss agent.
p value not available
31. Prevention of Obesity and Diabetes:
Principles
1. Record weight and other measures
2. Record degree of obesity
3. Check for diabetes and prediabetes and metabolic syndrome
4. Lifestyle advice, smartphone apps
5. Physical activity
6. Smoking cessation
7. Treat hypertension and lipids
8. Medication for obesity and diabetes